3 ms·
They also would simply refuse to research and develop any new drugs under that regulatory environment. Drug companies are. not benevolent entities, they are as
by FullMtlAlcoholc 10y ago
They also would simply refuse to research and develop any new drugs under that regulatory environment. Drug companies are. not benevolent entities, they are as cuththroat, or even moee so than Wall Street.
The real issue is the cost and length of clinical trials. I know this can be lowered somewhat by allowing computational models, but it is a difficult problem to solve unless biotech goes through the same garage Revolution as the PC
- gwright 10y agoOne way to address this is to create different standards of evaluation and to adjust the legal liabilities accordingly. What I mean (very roughly) is something like: Untested => you are on your own, don't imagine you can sue anyone if something goes wrong, this is the default Conditional => some basic efficacy/safety protocols have been evaluated, some limited liability for the drug companies, Approved => full suite of evaluation done, liability still capped but at a much higher level then Conditional There would still be legal safeguards around fraudulent or negligent practices of course that wouldn't be constrained by the capped liability I suggested above.